WESTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health (OPK) company, today announced results from a Phase 1 clinical study of SAR441236, its trispecific broadly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results